Starling Oncology, Inc. STLNW
0.01 USD 0.00 (-16.67%)
At closeNov 6, 2026, 4:00 PM EST
0.02 0.00 +21.60%
After hours · Nov 6, 4:00 PM ET
0.008 Day range 0.0185
0.0125 52-week range 0.0125
- YTD
- 0.00%
- 1 year
- 0.00%
Financial health
Altman Z-Score
0.80 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -6.6×
FY 2025 5y median -6.6× FY 2025
P/S 0.7×
FY 2025 5y median 0.7× FY 2025
P/B -20.9×
FY 2025 5y median -20.9× FY 2025
P/FCF -11.8×
FY 2025 5y median -11.8× FY 2025
EV/EBITDA -9.4×
FY 2025 5y median -9.4× FY 2025
EV/Sales 0.8×
FY 2025 5y median 0.8× FY 2025
FCF Yield -8.4%
FY 2025 5y median -8.4% FY 2025
Profitability
Gross Margin 15.2%
FY 2025 5y median 15.2% FY 2025
Operating Margin -7.2%
FY 2025 5y median -7.2% FY 2025
Net Margin -12.1%
FY 2025 5y median -12.1% FY 2025
ROE 385.5%
FY 2025 5y median 385.5% FY 2025
ROIC -35.7%
FY 2025 5y median -35.7% FY 2025
ROA -36.8%
FY 2025 5y median -36.8% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2025 FY 2025
Operating Income 0.0%
FY 2025 FY 2025
EPS (diluted) 0.0%
FY 2025 FY 2025
Free Cash Flow 0.0%
FY 2025 FY 2025
Financial Health
Current Ratio 1.6×
FY 2025 5y median 1.6× FY 2025
Quick Ratio 1.4×
FY 2025 5y median 1.4× FY 2025
Debt / Equity -6.6×
FY 2025 5y median -6.6× FY 2025
Net Debt / EBITDA -1.6×
FY 2025 5y median -1.6× FY 2025
Interest Coverage -3.2×
FY 2025 5y median -3.2× FY 2025
Dividends
Dividend Yield 0.0%
FY 2025 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2025 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31